Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

July 25, 2019 e-Pearl of the Week: Late-onset myoclonic epilepsy in Down syndrome (LOMEDS)

Late-onset myoclonic epilepsy in Down syndrome (LOMEDS)

Late-onset myoclonic epilepsy in Down syndrome (LOMEDS) is a progressive epilepsy characterized by development of myoclonus, tonic/clonic seizures, and gradual cognitive and functional decline in patients with Down syndrome (DS) over age 40¹.  Prevalence reaches 46% in patients over age 50². Accumulation of beta-amyloid plaques contributes to the development of myoclonic epilepsy in both DS with Alzheimer Disease (AD) and the general AD population². Differential diagnosis includes Lance-Adams syndrome and Unverrich-Lundborg disease.  EEG findings may show generalized spike-wave, polyspike-wave, or diffused slowing¹. Treatment suggestions are levetiracetam and valproate¹˒².

References

1. J. Möller, H. Hamer, W. Oertel, F. Rosenow.  Late-myoclonic epilepsy in Down’s syndrome. Seizure 2001; 10: 303-305. doi:10.1053/seiz.2000.0500

2. R. Simone, X. Puig, P. Géllisse, A.Grespel, P.Genton. Senile myoclonic epilepsy: Delineation of a common condition associated with Alzheimer’s disease in Down’s syndrome. Seizure 2010; 19: 3 83-389. doi:10.1016/j.seizure.2010.04.008

 

Submitted by Angela Welty, MSN, RN, ACNP-BC, Acute Care Nurse Practitioner, Sugar Land Neurology and Sleep, Texas, and Faisal Khan, MD, D, ABSM, DABPN, Consultant Neurologist, Sugar Land Neurology and Sleep, Texas.

Angela Welty and Dr. Khan report no disclosures.

Neurology: 96 (2)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise